Evidence map›Paper›PMID 21920706›Full record

ArticleInternational journal of antimicrobial agents2011

Bioactivity of WLBU2 peptide antibiotic in combination with bioerodible polymer.

J R McClanahan, R Peyyala, R Mahajan, R C Montelaro, K F Novak, D A Puleo

Abstract read
In one paragraph

Article in International journal of antimicrobial agents, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Targeted antimicrobial peptides.Frontiers in immunology · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

J R McClanahanCenter for Biomedical Engineering, University of Kentucky, Lexington, KY 40506-0070, USA.
R Peyyala
R Mahajan
R C Montelaro
K F Novak
D A Puleo
University of Kentucky · USUniversity of Pittsburgh · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Devices for Treating Inflammatory Bone Loss in an Oral EnvironmentR01DE019645 · NIDCR · UNIVERSITY OF KENTUCKY · PI PULEO, DAVID A. · 2009 to 2010
$801k
Analyses of Host-Biofilm Interactions: A Novel Polymicrobial ModelR21DE018177 · NIDCR · UNIVERSITY OF KENTUCKY · PI NOVAK, KAREN F. · 2008 to 2009
$403k
NCATS NIH HHS UL1 TR000005NIDCR NIH HHS DE018177NIDCR NIH HHS R01 DE019645NIDCR NIH HHS R21 DE018177
6 · The paper itself

Abstract

WLBU2 is a peptide antibiotic designed for broad antimicrobial activity, including bacteria associated with periodontal disease. Although periodontitis is associated with various systemic conditions, ranging from cardiovascular disease to preterm birth, local therapy is needed to treat the source of infection. Biodegradable polymers are often used to control locally the amount and rate of delivery of drugs. In the present study, a bioerodible association polymer comprising cellulose acetate phthalate (CAP) and Pluronic F-127 (PF-127) was explored for its interaction with WLBU2. The intrinsic antimicrobial activity of CAP/PF-127 and the combined effects of the polymer and WLBU2 were examined using Streptococcus gordonii, a species involved in early colonisation of tooth surfaces. The polymer blend alone had dose-dependent bacteriostatic properties, resulting in a ≥ 2 log decrease in colonies at the highest concentrations tested, possibly due to the hydrophobicity of CAP disrupting the surface of bacteria. When WLBU2 was combined with CAP/PF-127, an apparent binding of peptide to polymer significantly decreased the activity compared with free WLBU2, which functions like other cationic peptides by destabilising the bacterial membrane. Formulation with sucrose as an excipient, which reduced the interaction between WLBU2 and polymer, restored the bactericidal activity of the peptide antibiotic as reflected by a > 3 log decrease in S. gordonii. WLBU2 can be locally delivered using CAP/PF-127 as a release vehicle, with the peptide's bactericidal activity dominating the polymer's bacteriostatic effect.

Indexed as

Anti-Bacterial AgentsAntimicrobial Cationic PeptidesCelluloseDrug CarriersEscherichia coliHumansMicrobial Sensitivity TestsPoloxamerPolymersStreptococcus gordoniiAnti-Bacterial AgentsAntimicrobial Cationic PeptidesCellulosecellulose acetate phthalateDrug CarriersPoloxamerPolymersWLBU2 peptide

Identifiers

PMID21920706
PMCPMC3206138
OpenAlexW2077694217

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.